RE:RE:NEO is krapIt is still a very new exchange and things are not all ironed out. I guess you can see some links with BioCloud, you have to hope we have enough early adopters that will take a risk getting something completely new. Given the sales projections, I saw no need to rush to an uplisting, especially Naz which I understand is very expensive. So, we either may be heading to an uplisting prematurely or Ghezzi is holding back some much more promising information. Two options that are not that well managed from shareholders' perspective IMO.